Next Article in Journal
Crude α-Mangostin Suppresses the Development of Atherosclerotic Lesions in Apoe-Deficient Mice by a Possible M2 Macrophage-Mediated Mechanism
Previous Article in Journal
Association between Polymorphisms of OCT1 and Metabolic Response to Metformin in Women with Polycystic Ovary Syndrome
Open AccessCommunication

Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases

1
CNRS, INCIA, UMR 5287, F-33000 Bordeaux, France
2
University of Bordeaux, INCIA, UMR 5287, F-33000 Bordeaux, France
3
Department of Nuclear Medicine, University Hospital of Bordeaux, F-33000 Bordeaux, France
4
Department of Pathology, University Hospital of Martinique, 97261 Fort de France, France
5
Surgical Pathology unit, Department of BioPathology, Institut Bergonié, F-33076 Bordeaux, France
6
INSERM, ACTION U1218, F-33076 Bordeaux, France
7
Department of Urology, University Hospital of Toulouse, F-31000 Toulouse, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(7), 1721; https://doi.org/10.3390/ijms20071721
Received: 1 March 2019 / Revised: 27 March 2019 / Accepted: 1 April 2019 / Published: 7 April 2019
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Neurotensin and its high-affinity receptor, NTR1, are involved in the growth of various tumors. Few data are available regarding NTR1 expression in normal and tumoral human prostate tissue samples. NTR1 expression was assessed using immunohistochemistry in 12 normal prostate tissues, 11 benign prostatic hyperplasia (BPH), 44 prostate cancers, and 15 related metastatic lymph nodes (one per patient, when available). NTR1-staining was negative in normal prostate and BPH samples. NTR1 was overexpressed in four out of 44 (9.1%) primary tumors. There was no clear association between NTR1 overexpression and age, PSA-values, Gleason score, pT-status, nodal-status, or margin. NTR1 was expressed at a high level of five out of 15 (33.3%) metastatic lymph nodes. NTR1 overexpression was thus more frequent in metastatic lymph nodes than in primary tumors (p = 0.038). In this limited series of samples, NTR1 overexpression was observed in few primary prostate cancers. Upregulation was more frequent in related lymph nodes. The presence of this target in metastatic lymph nodes may open new perspectives for imaging and radionuclide therapy of prostate cancer. Factors driving NTR1 expression in primary prostate cancer and in nodal and distant metastases still need to be characterized. View Full-Text
Keywords: neurotensin receptor-1; NTR1; prostate cancer; neuropeptide neurotensin receptor-1; NTR1; prostate cancer; neuropeptide
Show Figures

Graphical abstract

MDPI and ACS Style

Morgat, C.; Chastel, A.; Molinie, V.; Schollhammer, R.; Macgrogan, G.; Vélasco, V.; Malavaud, B.; Fernandez, P.; Hindié, E. Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. Int. J. Mol. Sci. 2019, 20, 1721.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop